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Vaccine manufacturing targeting animal and human prophylaxis has been relying heavily on the use of sera to 
reach adequate titers in mammalian cell culture processes. Safety concerns, lack of process robustness, costs of 
qualification, supply and storage are some of the main challenges faced while using sera. Taking into account 
these drawbacks, sera has remained one of the principal raw materials in vaccine manufacturing, but with limited 
supply worldwide and increased demands, notably from the cell therapy industry, sera’s poor economic 
predictability might become a major issue on cost of good models required for vaccine viability. Using Gibco’s 
expertise in designing and manufacturing cell culture media for the past 55 years, we identified 4 approaches to limit 
the use of serum in viral processes. The first strategy to require limited process rework is by reducing the amount of 
serum in vaccine manufacturing through use of enriched basal media and/or bovine serum albumin as a substitute. 
The second option is to identify which step of the manufacturing process actually requires serum 
supplementation. Indeed, while cell growth in adherent conditions may require sera for expansion, the production 
phase after infection can sometimes eliminate use of FBS or BSA supplementation, thus simplifying processes 
and compliance to regulatory guidelines. The third approach, providing virus production is not adherence- 
dependent, is to adapt the adherent cell line to suspension culture, hence removing the need to provide 
attachment factors present in sera. Finally, when available, a completely controlled process can be developed 
using cells adapted to  CD media (chemically-defined and  protein-free). The Gibco perspective on vaccine 
technology is to streamline workflows while providing media capabilities to support vaccine manufacturers at large 
scale. This work will demonstrate that implementing a well-designed strategy to reduce or remove sera from 
current processes is an effective way to achieve a more robust and scalable viral process. 
    
 
